Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010

Cancer

Volumn 119, Issue 23, 2013, Pages 4196-4204

  Cai, Sophie ^a   Hong, Theodore S ^b   Goldberg, Saveli I ^b   Fernandez Del Castillo, Carlos ^b   Thayer, Sarah P ^b   Ferrone, Cristina R ^b   Ryan, David P ^b   Blaszkowsky, Lawrence S ^b   Kwak, Eunice L ^b   Willett, Christopher G ^c   Lillemoe, Keith D ^b   Warshaw, Andrew L ^b   Wo, Jennifer Y ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

chemotherapy; locally advanced; pancreatic cancer; radiotherapy; survival

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL EVALUATION; CONTINUOUS INFUSION; DISTANT METASTASIS FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GENERAL HOSPITAL; HUMAN; INOPERABLE CANCER; INTRAOPERATIVE RADIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREND STUDY;

CHEMOTHERAPY; LOCALLY ADVANCED; PANCREATIC CANCER; RADIOTHERAPY; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTRAOPERATIVE PERIOD; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RETROSPECTIVE STUDIES;

EID: 84887993212     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28329     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Huguet F, Goodman KA, Azria D, Racadot S, Abrams RA,. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. Int J Radiat Oncol Biol Phys. 2012; 83: 1355-1364.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. nccn.org/professionals/physician-gls/ pdf/pancreatic.pdf. Accessed November 21, 2012.
4. Wood WC, Shipley WU, Gunderson LL, Cohen AM, Nardi GL,. Intraoperative irradiation for unresectable pancreatic carcinoma. Cancer. 1982; 49: 1272-1275.
5. Willett CG, Del Castillo CF, Shih HA, et al. Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg. 2005; 241: 295-299.
6. Charlson M, Szatrowski TP, Peterson J, Gold J,. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47: 1245-1251.
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
8. Ogawa K, Karasawa K, Ito Y, et al. Intraoperative radiotherapy for unresectable pancreatic cancer: a multi-institutional retrospective analysis of 144 patients. Int J Radiat Oncol Biol Phys. 2011; 80: 111-118.
9. Okamoto A, Matsumoto G, Tsuruta K, et al. Intraoperative radiation therapy for pancreatic adenocarcinoma: the Komagome hospital experience. Pancreas. 2004; 28: 296-300.
10. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009; 27: 1806-1813.
11. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008; 19: 1592-1599.
12. Arvold ND, Ryan DP, Niemierko A, et al. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer. 2012; 118: 3026-3035.
13. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007; 110: 47-55.
14. Hammel P, Huguet F, Van Laethem JL, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. Paper presented at: ASCO Annual Meeting; May 31-June 4, 2013; Chicago, IL.
15. Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-1825.
16. Von Hoff DD, Ervin TJ, Arena FP, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). Paper presented at: 2013 Gastrointestinal Cancers Symposium; January 24-26, 2013; San Francisco, CA.
17. Mahadevan A, Miksad R, Goldstein M, et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys. 2011; 81: e615-e622.
18. Schellenberg D, Kim J, Christman-Skieller C, et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011; 81: 181-188.
19. Martin RC 2nd, McFarland K, Ellis S, Velanovich V,. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival [published online ahead of print November 6, 2012 ]. Ann Surg Oncol.
20. Iversen LH, Norgaard M, Jacobsen J, Laurberg S, Sorensen HT,. The impact of comorbidity on survival of Danish colorectal cancer patients from 1995 to 2006-a population-based cohort study. Dis Colon Rectum. 2009; 52: 71-78.
21. Koppie TM, Serio AM, Vickers AJ, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer. 2008; 112: 2384-2392.
22. Ouellette JR, Small DG, Termuhlen PM,. Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg. 2004; 8: 1061-1067.
23. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr,. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004; 291: 2441-2447.
24. Reid BC, Alberg AJ, Klassen AC, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer. 2001; 92: 2109-2116.
25. Vickers MM, Powell ED, Asmis TR, et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer- results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer. 2012; 48: 1434-1442.
26. Nakai Y, Isayama H, Sasaki T, et al. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Crit Rev Oncol Hematol. 2011; 78: 252-259.
27. Shimoda M, Katoh M, Kita J, Sawada T, Kubota K,. The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer. Chemotherapy. 2010; 56: 501-506.
28. Chu CK, Mazo AE, Goodman M, et al. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol. 2010; 17: 502-513.